Canton Strategic Holdings, Inc. (CNTN)

Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., is a New York-based company that combines a digital asset treasury strategy with a clinical-stage biotechnology business.

Its digital asset segment centers on Canton Coin, the native token of the Canton Network, a blockchain designed for institutional finance; the company holds the token and participates in network activities such as running validator operations. Its biotechnology segment continues development of drug candidates inherited from Tharimmune, including GV104, a buccal film formulation of nalmefene intended to counter opioid-induced respiratory depression, and GV023, an oral antibody targeting tumor necrosis factor-alpha. Its common stock trades on Nasdaq under the ticker CNTN.